Backs FY23 revenue view $5.9B-$6.1B, consensus $5.97B. Edwards Lifesciences will discuss the company’s focus and strategy for longer-term growth, provide an update on its technology pipeline and share financial guidance during its annual investor conference.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences price target lowered to $80 from $82 at RBC Capital
- Edwards Lifesciences price target lowered to $80 from $102 at Morgan Stanley
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Boeing upgraded, Shopify downgraded: Wall Street’s top analyst calls
- Edwards downgraded to Underperform from Peer Perform at Wolfe Research
